[go: up one dir, main page]

WO2025211626A1 - Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau - Google Patents

Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau

Info

Publication number
WO2025211626A1
WO2025211626A1 PCT/KR2025/003734 KR2025003734W WO2025211626A1 WO 2025211626 A1 WO2025211626 A1 WO 2025211626A1 KR 2025003734 W KR2025003734 W KR 2025003734W WO 2025211626 A1 WO2025211626 A1 WO 2025211626A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
compound
skin
body weight
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2025/003734
Other languages
English (en)
Korean (ko)
Inventor
김아영
조시영
정지용
김동현
홍용덕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of WO2025211626A1 publication Critical patent/WO2025211626A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present disclosure relates to a composition for improving skin turnover cycle containing compound K.
  • the epidermis maintains a constant skin turnover cycle through continuous keratin formation and shedding. If the skin turnover cycle is not maintained and becomes shorter or longer, the normal functions of the epidermis, including the skin's ability to defend itself against irritation, are lost.
  • the skin turnover cycle is a repetitive process in which keratinocytes in the basal layer of the skin proliferate and differentiate, ascending to the stratum corneum to form new keratinocytes and shed the existing stratum corneum.
  • the proliferation of keratinocytes is an important factor in regulating the skin turnover cycle.
  • Patent Document 1 Republic of Korea Patent Publication No. 10-2014-0003198
  • the present disclosure provides a composition that effectively restores the skin turnover cycle, which is prolonged due to inhibition of epidermal cell proliferation, by increasing the expression of p63 and KLF4, which are markers related to keratinogenesis and stem cell potential in the epidermal layer, thereby enabling keratinocytes to continuously self-replicate and promoting cell division to enable continuous keratinogenesis.
  • one embodiment of the present invention provides a composition for improving skin turnover cycle containing compound K.
  • composition for improving the skin turnover cycle can effectively restore the skin turnover cycle that is prolonged due to inhibition of epidermal cell proliferation by increasing the expression of p63 and KLF4, which are markers related to keratinogenesis and stem cell potential in the epidermal layer, thereby enabling keratinocytes to continuously self-replicate and promoting cell division to enable continuous keratinogenesis.
  • Figure 1 shows the results of a skin cytotoxicity test of compound K.
  • Figures 2a and 2b show the results of confirming changes in the expression of p63 and KLF4 in an environment of accelerated skin aging caused by UVB treatment.
  • Figures 3a and 3b show the results of confirming changes in the expression of p63 and KLF4 in an environment of accelerated skin aging caused by fine dust (PM2.5) treatment.
  • Figures 4a and 4b show the results of confirming changes in the expression of p63 and KLF4 in an environment of accelerated skin aging caused by blue light (HEV) treatment.
  • HEV blue light
  • Figures 5a to 5c show the results of confirming the efficacy of compound K on artificial skin for accelerated skin aging by UVB treatment.
  • the present invention may relate to a composition for improving skin turnover cycle containing compound K.
  • the present invention may relate to a method for improving skin turnover cycle, comprising applying or administering an effective amount of compound K to a subject in need thereof.
  • the present invention may relate to a compound K for use in improving skin turnover cycle.
  • the present invention may relate to non-therapeutic uses of compound K for improving skin turnover cycle.
  • the compound K may be represented by the following chemical formula 1.
  • the compound K may be contained in an amount of 0.0002 to 0.04 wt% relative to the total weight of the composition. Specifically, the compound K may be included in an amount of 0.0002 wt% or more, 0.0003 wt% or more, 0.0004 wt% or more, 0.0005 wt% or more, 0.0006 wt% or more, 0.0007 wt% or more, 0.0008 wt% or more, 0.0009 wt% or more, 0.001 wt% or more, 0.002 wt% or more, 0.003 wt% or more, 0.004 wt% or more, 0.005 wt% or more, 0.006 wt% or more, 0.007 wt% or more, 0.008 wt% or more, 0.009 wt% or more, 0.01 wt% or more, or 0.02 wt% or more, relative to the total weight of the composition, and further, the compound K may be included in an amount of
  • the compound K can increase the expression of p63.
  • the compound K can increase the expression of KLF4.
  • p63 is a marker that regulates the division and differentiation of keratinocytes. A decrease in p63 inhibits keratinocyte division and thus keratinogenesis.
  • KLF4 is a marker related to stem cell potential, and a decrease in KLF4 indicates a decrease in stem cell potential. Decreased expression of p63 and KLF4 in skin keratinocytes indicates a loss of the proliferative function of the epidermis. Therefore, the regulation of p63 and KLF4 expression is crucial for regulating the skin turnover cycle in the epidermis.
  • the compound K can increase the expression of one or more of p63 and KLF4 in keratinocytes of the epidermal layer.
  • the compound K can improve skin turnover cycle in the epidermal layer by increasing the expression of one or more of p63 and KLF4.
  • the daily dose of the compound K may be 0.5 mg/kg body weight to 10 mg/kg body weight.
  • the daily application amount, application amount or intake amount of the compound K is 0.5 mg/kg (body weight) or more, 1 mg/kg (body weight) or more, 1.5 mg/kg (body weight) or more, 2 mg/kg (body weight) or more, 2.5 mg/kg (body weight) or more, 3 mg/kg (body weight) or more, 3.5 mg/kg (body weight) or more, 4 mg/kg (body weight) or more, 4.5 mg/kg (body weight) or more, 5 mg/kg (body weight) or more, 5.5 mg/kg (body weight) or more, 6 mg/kg (body weight) or more, 6.5 mg/kg (body weight) or more, 7 mg/kg (body weight) or more, 7.5 mg/kg (body weight) or more, 8 mg/kg (body weight) or more, 8.5 mg/kg (body weight) or more, 9 mg/kg (body weight) or more or 9.5 mg/
  • the composition may be a cosmetic composition.
  • the cosmetic composition according to one embodiment of the present invention may contain a cosmetically or dermatologically acceptable medium or base.
  • a cosmetically or dermatologically acceptable medium or base may be provided in any formulation suitable for topical application, for example, in the form of a solution, gel, solid, anhydrous paste, an emulsion obtained by dispersing an oil phase in an aqueous phase, a suspension, a microemulsion, a microcapsule, a microgranule, or a vesicular dispersion of ionic (liposomes) and non-ionic types, or in the form of a cream, toner, lotion, powder, ointment, spray, or concealer stick.
  • These compositions may be prepared according to methods conventional in the art.
  • the cosmetic composition may also be used in the form of an aerosol composition further containing a propellant compressed in the form of a foam.
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether may be additionally included.
  • a solvent, solvating agent or emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
  • the composition may also contain ingredients typically found in cosmetic compositions, as needed.
  • ingredients to be included include, but are not limited to, oil-based ingredients, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, bactericides, antioxidants, plant extracts, pH regulators, alcohols, pigments, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, and the like.
  • the composition may be a non-therapeutic oral composition or a food composition.
  • the dosage form of the above non-therapeutic oral composition or food composition is not particularly limited, but may be formulated as, for example, tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc.
  • the non-therapeutic oral composition or food composition of each dosage form can be appropriately selected and combined by a person skilled in the art according to the dosage form or purpose of use by appropriately selecting the ingredients commonly used in the relevant field, and a synergistic effect may occur when applied simultaneously with other raw materials.
  • the above composition can be administered in various ways such as simple ingestion, drinking, injection administration, spray administration, or squeeze administration.
  • the determination of the dosage or intake amount of the active ingredient is within the level of a person skilled in the art, and may vary depending on various factors such as the age, health condition, and complications of the subject to be administered or consumed.
  • a non-therapeutic oral composition or food composition according to one embodiment of the present invention may be, for example, various food products such as chewing gum, caramel products, candy, ice cream, and confectionery, beverage products such as soft drinks, mineral water, and alcoholic beverages, and oral products containing vitamins or minerals.
  • the present invention may provide, as an example, the following embodiments.
  • the first embodiment can provide a composition for improving skin turnover cycle containing compound K.
  • a third embodiment can provide a composition according to at least one of the first embodiment and the second embodiment, wherein the compound K increases the expression of p63.
  • a fifth embodiment can provide a composition according to one or more of the first to fourth embodiments, wherein the compound K improves the skin turnover cycle in the epidermal layer.
  • the seventh embodiment can provide a composition according to at least one of the first to sixth embodiments, wherein the daily application amount of the compound K is 0.5 mg/kg (body weight) to 10 mg/kg (body weight).
  • the eighth embodiment can provide a composition that is a cosmetic composition according to one or more of the first to seventh embodiments.
  • the ninth embodiment can provide a composition that is a non-therapeutic oral composition according to one or more of the first to eighth embodiments.
  • human epidermal keratinocytes were seeded at 1x104 in a 96-well plate and cultured for 24 hours. The cells were then treated with Compound K at final concentrations of 0.5 ppm, 1 ppm, 2 ppm, and 4 ppm per well, respectively, and cultured for 24 hours. 10 ⁇ l of Cell Counting Kit- 8 (CCK-8) solution was added to each well and cultured at 37°C for 2 hours. The absorbance was measured at 450 nm, and the cell proliferation and toxicity effects were calculated as a percentage based on the absorbance of the control group. The results are shown in Fig. 1.
  • human epidermal keratinocytes were seeded at 1x104 in a 96-well plate, cultured for 24 hours, and then treated with Compound K at concentrations of 0.5 ppm, 1 ppm, 2 ppm, and 4 ppm. After 30 minutes, IL-17A was additionally treated to the medium at a concentration of 50 ⁇ g/ml, and after 24 hours, the culture medium was removed, replaced with PBS, and irradiated with 20 mJ/ cm2 of ultraviolet (UVB) and cultured for 24 hours.
  • UVB ultraviolet
  • human epidermal keratinocytes were seeded at 1x104 in a 96-well plate, cultured for 24 hours, and then treated with Compound K at a concentration of 2 ppm. After 30 minutes, IL-17A was additionally added to the medium at a concentration of 50 ⁇ g/ml. After 24 hours, the culture medium was removed, replaced with PBS, and irradiated with blue light (HEV) at 40 J/ cm2 . The medium was replaced with IL-17A at a concentration of 50 ⁇ g/ml and Compound K at a concentration of 2 ppm, and cultured for an additional 24 hours.
  • HEV blue light
  • human epidermal keratinocytes were seeded at 1x104 in 96-well plates and cultured for 24 hours. Then, an inflammatory response was induced by treating the medium with 50 ⁇ g/ml of IL-17A, an inflammatory aging factor. After 24 hours, the culture medium was removed and replaced with PBS, and then irradiated with 20 mJ/ cm2 of ultraviolet (UVB) light, 100 ⁇ g/ml of fine dust (PM2.5), or 40 J/ cm2 of high-energy emitted (HEV) light. After replacing the medium with 50 ⁇ g/ml of IL-17A and 2ppm of Compound K, the cells were cultured for an additional 24 hours.
  • UVB ultraviolet
  • PM2.5 fine dust
  • HEV high-energy emitted

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

La présente divulgation concerne une composition pour améliorer un cycle de renouvellement de la peau, qui comprend du composé K. Plus particulièrement, la composition pour améliorer un cycle de renouvellement de la peau selon la présente invention accroît l'expression de p63 et KLF4, qui sont des marqueurs associés à la formation des kératinocytes et au caractère souche dans l'épiderme, de telle sorte que les kératinocytes peuvent être auto-répliqués en continu et peuvent subir une formation de kératine prolongée par promotion de la division cellulaire, ce qui permet de restaurer efficacement un cycle de renouvellement de la peau à partir du cycle prolongé provoqué par la suppression de la prolifération des cellules de l'épiderme.
PCT/KR2025/003734 2024-04-04 2025-03-24 Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau Pending WO2025211626A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2024-0045898 2024-04-04
KR1020240045898A KR20250147435A (ko) 2024-04-04 2024-04-04 컴파운드 k를 함유하는 피부 턴오버 주기 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2025211626A1 true WO2025211626A1 (fr) 2025-10-09

Family

ID=97267752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2025/003734 Pending WO2025211626A1 (fr) 2024-04-04 2025-03-24 Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau

Country Status (2)

Country Link
KR (1) KR20250147435A (fr)
WO (1) WO2025211626A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101928797B1 (ko) 2012-06-29 2018-12-17 (주)아모레퍼시픽 컴파운드 ｋ를 함유하는 피부 외용제 조성물

Also Published As

Publication number Publication date
KR20250147435A (ko) 2025-10-13

Similar Documents

Publication Publication Date Title
WO2013027984A2 (fr) Composition cosmétique contenant un composant de thé vert
WO2011122840A2 (fr) Inhibiteur pour la mélanine, et composition cosmétique contenant celui-ci
WO2022177217A2 (fr) Composition pour la régénération, le blanchiment, l'antioxydation de la peau, ou le traitement des plaies, comprenant un exosome dérivé de cellules souches utilisé en tant que principe actif, et utilisation associée
WO2012067404A2 (fr) Composition anti-vieillissement contenant artemisia annua l. comme principe actif
WO2012070804A2 (fr) Composition cosmétique contenant un acide oléanolique
WO2018164369A1 (fr) Composition pour améliorer les rides de la peau, contenant un extrait d'hibiscus syriacus traité par une enzyme en tant que principe actif
KR101860109B1 (ko) 플로랄진세노사이드를 함유하는 피부 외용제 조성물
WO2019107831A2 (fr) Composition pour prévenir ou améliorer le vieillissement intrinsèque comprenant de la paéoniflorine ou de l'albiflorine
WO2019143055A1 (fr) Composition comprenant un extrait de haricots fermentés obtenu à partir d'une fermentation par une souche d'aspergillus fumigatus, pour l'amélioration de soins cutanés
KR101551243B1 (ko) 말굽버섯 추출물을 포함하는 피부미백용 화장료 조성물
KR20180081328A (ko) 상백피 추출물을 유효성분으로 포함하는 피부외용제 조성물
JPH1029924A (ja) 抗老化剤
WO2025211626A1 (fr) Composition contenant du composé k pour améliorer le cycle de renouvellement de la peau
JPH1029927A (ja) 抗老化剤
KR101877803B1 (ko) 플로랄진세노사이드를 함유하는 피부 외용제 조성물
WO2025211624A1 (fr) Composition contenant le composé k permettant d'améliorer ou d'augmenter l'éclat ou la transparence de la peau
WO2020101414A1 (fr) Composition favorisant la régénération cutanée et la poussée capillaire, contenant de l'apigénine
WO2020091295A1 (fr) Composition comprenant un extrait d'écorce d'ailanthus altissima en tant que principe actif pour le soin de la peau acnéique ou l'inhibition de la sécrétion de sébum
KR20210076566A (ko) 미세먼지로부터 피부를 보호하는 화장료 조성물 및 이의 제조 방법
WO2025211625A1 (fr) Composition contenant du composé k pour réduire le relâchement cutané
KR100710657B1 (ko) 디하이드로퀘세틴을 함유하는 미백 화장료 조성물
WO2022139458A1 (fr) Composition de soins de la peau
KR100427556B1 (ko) 루시놀을 함유하는 화장료 조성물
KR20100138164A (ko) 말 태반 추출물을 이용한 피부 외용제 조성물
KR101273027B1 (ko) 캄페롤을 유효성분으로 함유하는 피지 분비 억제용 및항비만용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25782829

Country of ref document: EP

Kind code of ref document: A1